Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03219333
Title A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)
Acronym EV-201
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | FRA | ESP | DEU


No variant requirements are available.